Objective of this study is: to determine efficacy and safety of a Esflurbiprofen Hydrogel Patch compared to placebo in patients with acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuries. to demonstrate that the Esflurbiprofen Hydrogel Patch is superior to placebo, and that the patch has acceptable local tolerability.
Study Design Randomized (1:1) (stratified by center and 2 subgroups), controlled, double-blind, multi-centric study in parallel groups. Patient Population/Sample size/Study Sites The clinical trial population will consist of male or female patients, 18 - 60 years suffering from acute; strains, sprains or bruises of the extremities following blunt trauma, and meeting all clinical trial entry criteria. 200 patients will be enrolled (assumes a drop-out-rate of ≤10%). The study will be performed in Germany in 3 sites
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
Esflurbiprofen is a cyclooxygenase (COX) inhibitor
Deutsche Sporthochschule Köln Institut für Kreislaufforschung und Sportmedizin
Cologne, North Rhine-Westphalia, Germany
Change of Pain-on-movement (POM) Compared to Baseline
Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Change from baseline to Visit 5 (72 hours after initiating treatment)
Pain-on-movement (POM) on VAS
Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Baseline and 12, 24, 48, 72, 96, 168 hours after initiating treatment
Area-under-the-curve for POM on VAS
Area-under-the-curve (AUC) over time during first 12, 24, 48, 72, 96 and 168 hours for Pain on movement (POM) measured using a VAS Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Baseline and 12, 24, 48, 72, 96, 168 hours after initiating treatment
Pain-at-rest on VAS
Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Baseline and 12, 24, 48, 72, 96, 168 hours after initiating treatment
Time to Meaningful and Optimal Reduction
The time taken to achieve a meaningful (30 %) and optimal (50 %) reduction of pain measured on the VAS for POM Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Baseline and 12, 24, 48, 72, 96, 168 (192) hours after initiating treatment
Time to Complete Resolution of Pain
Time to complete resolution of pain, i. e. reaching a POM VAS value of 0 mm after start of study treatment Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: Baseline and 12, 24, 48, 72, 96, 168 (192) hours after initiating treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Responder Rate 1
defined as the percentage of patients achieving ≥50% reduction from baseline in the VAS score for POM at 72 hours Visual Analogue Scale (VAS) 0 = "no pain", 100 = "Extreme pain"
Time frame: 72 hours
Global Efficacy Assessments 1 by Patient
The global efficacy was assessed by the patients. The patients answered question below; -Considering all the ways this treatment has affected you since you started the clinical trial, how well are you doing? (5-point Likert scale: 0 = very good, 1 = good, 2 = fair, 3 = poor, and 4 = very poor). \[Global efficacy assessment 1\]
Time frame: 48 h, 72 h, and 168 h
Global Efficacy Assessments 2 by Patient
The global efficacy was assessed by the patients. The patients answered question below -How do you rate this medication as treatment for your soft injury/contusion? (5-point Likert scale: 0 = excellent, 1 = very good, 2 = good, 3 = fair, and 4 = poor). \[Global efficacy assessment 2\]
Time frame: 48 h, 72 h, and 168 h
Global Efficacy Assessments 1 by Investigator
The global efficacy was assessed by the investigator. -Considering all the ways this treatment has affected you since you started the clinical trial, how well are you doing? (5-point Likert scale: 0 = very good, 1 = good, 2 = fair, 3 = poor, and 4 = very poor). \[Global efficacy assessment 1\]
Time frame: 48 h, 72 h, and 168 h
Use of Rescue Medication
Rescue medication (paracetamol, 500 mg tablets, up to 3000 mg daily) was allowed during the study, except for the 6 hours prior to V5 (72 h).
Time frame: 0-168h
Resolution of Soft Tissue Injury/Contusion
Resolution of soft tissue injury/contusion was assessed by the Investigator at Visit 7 (168h).
Time frame: 168h
SPID of POM VAS Changes
The sum of pain intensity difference (SPID) of POM on VAS changes over 0-24 h, 0-48 h, 0-72 h, and 0-96 h were calculated. SPID was calculated as the area under the curve of the VAS difference from baseline value.
Time frame: 0-24 h, 0-48 h, 0-72 h, and 0-96 h
Responder Rate 2 at 168h
defined as the percentage of patients able to resume training/normal physical activity by 168 hours
Time frame: 168h